Honda R, Fujita A, Inoue Y, Asakawa M, Suzuki A
Department of Internal Medicine, Sapporo Medical College, Japan.
Cancer Chemother Pharmacol. 1990;26(5):373-6. doi: 10.1007/BF02897297.
A total of 47 patients with unresectable non-small-cell lung cancer were treated with a regimen consisting of cisplatin (CDDP, 100 mg/m2), ifosfamide (IFX, 2 g/m2 x 3; with mesna) and vindesine (VDS, 3 mg/m2) (CIV). This regimen was given over a 3- or 5-week period. Among 40 completely evaluable patients, 19 partial responses (PRs) were observed, for a response rate of 47.5% (78.6% in squamous-cell carcinoma and 30.1% in adeno- and large-cell carcinoma); no complete responses (CRs) were obtained. The hematologic toxicity was not severe, but the renal toxicity was rather high; two patients developed acute renal failure and died of subsequent pancytopenia and sepsis. We concluded that the CIV regimen was more effective, especially against squamous-cell carcinoma, but more toxic than the combination of CDDP and VDS for non-small-cell lung cancer and that candidates for this therapy must be carefully chosen.
共有47例不可切除的非小细胞肺癌患者接受了由顺铂（CDDP，100mg/m²）、异环磷酰胺（IFX，2g/m²×3；加用美司钠）和长春地辛（VDS，3mg/m²）组成的方案（CIV）治疗。该方案在3周或5周内给予。在40例可完全评估的患者中，观察到19例部分缓解（PR），缓解率为47.5%（鳞状细胞癌为78.6%，腺癌和大细胞癌为30.1%）；未获得完全缓解（CR）。血液学毒性不严重，但肾毒性相当高；2例患者发生急性肾衰竭，随后死于全血细胞减少和败血症。我们得出结论，CIV方案对非小细胞肺癌更有效，尤其是对鳞状细胞癌，但比CDDP和VDS联合方案毒性更大，并且必须谨慎选择该治疗的候选患者。
